Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Particle therapy followed by durvalumab plus gemcitabine and cisplatin for unresectable intrahepatic cholangiocarcinoma
jRCTs051250168Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by AstraZeneca. Primary endpoint: Grade 3 or higher adverse events on treatment. Started Dec 2025; status: recruiting.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on jRCTs051250168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250168.